CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
MGI›
Library
MGI

MGI

MGI develops sequencing instruments, reagents, laboratory automation, and multi-omics tools for life science research.

Legal seat
Shenzhen, Guangdong, CN🇨🇳
Founded
2016
Loading
Overview
Compare
Employees
Library

MGI - Library

global-mgitech.com·Crawled Oct 2, 2026·

Topics

Publication type

Content origin
Row density

Product

6 pages
  1. MGI Tech Announces Upgraded MGISP-Smart 8: Revolutionizing Lab Automation Platform with Innovative Pipetting and Gripper Functions/mgisp-smart-8-automated-pipetting-system

    MGI launches MGISP-Smart 8, an advanced 8-channel automated pipetting system for flexible, high-throughput molecular diagnostics and lab automation.

  2. MGI Tech Empowers Life Sciences Industry with Revolutionary What If Campaign at XXIIIrd International Congress of Genetics/what-if-global-genomics-campaign

    MGI launches the global “What If?” campaign, showcasing genomics solutions, high-throughput sequencers, and lab automation to empower scientists worldwide.

  3. MGI Tech launches microbial isolates whole-genome sequencing package/mgi-tech-launches-microbial-isolates-whole-genome-sequencing-package

    The package aims to empower microbial genomics research with a comprehensive sequencing solution that offers a seamless operation experience with a 3-step-only library preparation design.

  4. MGI Tech launches microbiome metabarcoding sequencing package for advanced microbiome research/mgi-tech-launches-microbiome-metabarcoding-sequencing-package-for-advanced-microbiome-research

    Microbiomics explores the behavior, interaction, and function of microbial communities in specific environments. Microbiome sequencing represents a groundbreaking technology that allows researchers to delve into and understand the complexity of microbial communities in the human body and the environment, revealing the diversity, abundance, and function of microorganisms.

Blog

6 pages
  1. Interview with Carolina Aoki: lessons from driving success in Brazil’s genomics sector/interview-with-carolina-aoki-lessons-from-driving-success-in-brazils-genomics-sector

    Carolina Aoki, a dedicated Technical Sales Specialist from our Brazil team. Reflecting on her remarkable achievements in 2024, Carolina highlighted two major milestones: successfully closing the Sabin Group deal and securing a strategic partnership with GDM.

  2. Interview with Lewis Lusuwi: Breakthrough in lab automation with the first regional clinical customer/interview-with-lewis-lusuwi-breakthrough-in-lab-automation-with-the-first-regional-clinical-customer

    Today we spoke with Lewis B. T. Lusuwi from Australia team. As a field application scientist focused on automation, he shared how he and the team have innovatively made adaptions of automation products to meet client needs. Dive into the interview to learn more about Lewis’s experiences during this extraordinary…

  3. Interview with Manuel Delpero: from field expertise to team leadership/interview-with-manuel-delpero-from-field-expertise-to-team-leadership

    In 2024, Manuel Delpero from MGI Europe and Africa team get promoted from a Field Bioinformatics Scientist (FBS) to the role of Associate Manager of Field Application Scientists (FAS), marking a significant milestone in his career.

  4. Interview with Tommy Li: collaborative success against cultural difference/interview-with-tommy-li-collaborative-success-against-cultural-difference

    Today, we spoke with Tommy Li, the Channel Manager from the MGI APAC team. The year 2024 has been an unconventional one for Tommy and the regional team: even though faced with challenges on multiple fronts, they still achieved significant growth in both distribution revenue and market coverage. As a…

Press

1 page
  1. World Cancer Day: advancing precision cancer care with OncoDNA & MGI/world-cancer-day-advancing-precision-cancer-care-with-oncodna-mgi-copy

    As we celebrate World Cancer Day, we’re spotlighting the transformative impact of genomics in precision medicine for oncology. The theme of World Cancer Day 2025 is “United by Uniquel”, today in the latest episode of the MGI podcast, we invite industry experts shared their insights on the evolving landscape of…

About

1 page
  1. Dr. Radoje Drmanac: A lifelong journey of Genomic discovery/a-lifelong-journey-of-genomic-discovery

    A Lifelong Journey of Genomic Discovery: Reflecting on A Decade of DNBSEQ Innovation and Beyond. This year, we are not just celebrating a milestone; we are embracing the limitless possibilities of DNBSEQ that lie ahead.

Homepage

2 pages
  1. Homepage/

    Discover DNBSEQ sequencers, CycloneSEQ long-read tech, spatial omics and lab automation. Explore MGI Tech platforms for research and clinical genomics.

  2. MGI 5g Smart Healthcare Partnership/mgi-5g-smart-healthcare-partnership

    BGI and MGI partner with China Mobile to advance 5G smart healthcare, enabling remote ultrasound, gene sequencing, AI applications, and telemedicine solutions.